Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia

Keyphrases

• Acute Lymphoblastic Leukemia 100%
• High-dose Methotrexate (HD-MTX) 100%
• Pharmacodynamic Study 100%
• Methotrexate 71%
• Childhood Acute Lymphoblastic Leukemia 28%
• Clinical Response 28%
• Systemic Exposure 28%
• 6-mercaptopurine (6-MP) 28%
• Significant Benefit 14%
• Complete Remission 14%
• Hematologic 14%
• Cancer Chemotherapy 14%
• Conventional Therapy 14%
• Drug Clearance 14%
• Remission 14%
• Drug Sensitivity 14%
• Intermediate Risk 14%
• Steady-state Plasma Concentration 14%
• Maintenance Therapy 14%
• Historical Controls 14%
• Potential Gains 14%
• Previously Untreated 14%
• Systemic Clearance 14%

Medicine and Dentistry

• Drug Megadose 100%
• Pharmacodynamics 100%
• Acute Lymphoblastic Leukemia 100%
• Methotrexate 100%
• Infusion 16%
• Mercaptopurine 16%
• Malignant Neoplasm 8%
• Low Drug Dose 8%
• Steady State 8%
• Maintenance Therapy 8%
• Cancer Chemotherapy 8%
• Drug Sensitivity 8%
• Drug Clearance 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacodynamics 100%
• Acute Lymphoblastic Leukemia 100%
• Methotrexate 100%
• Remission 16%
• Mercaptopurine 16%
• Malignant Neoplasm 8%
• Cancer Chemotherapy 8%